Boizeau Laure, Servant-Delmas Annabelle, Ducancelle Alexandra, Chevaliez Stéphane, Thibault Vincent, Laperche Syria, Cappy Pierre
National Institute of Blood Transfusion, Department of Blood-Borne Agents, National Reference Center for Infectious Risks in Transfusion, Paris, France.
Laboratory of Virology, Angers University Hospital, Angers, France.
J Clin Microbiol. 2020 Aug 24;58(9). doi: 10.1128/JCM.00647-20.
The high genetic variability of hepatitis B virus (HBV) can impair DNA quantification. Here, we investigate a major underquantification of HBV by the cobas TaqMan HBV assay (CTM; Roche). In France, between 2005 and 2017, HBV DNA was detected in 3,102 blood donations by use of the CTM (95% limit of detection [LOD], 4.8 IU/ml). HBV strains were sequenced in the S region (LOD, ∼30 IU/ml). Concordant ( = 120) and discordant ( = 45) samples were identified according to the agreement between the plasma viral load (pVL) determined by the CTM and sequencing; all samples were also quantified using the RealTime HBV assay (RTH; Abbott). The viral signature, cloning, and mutagenesis were used to characterize the polymorphism responsible for CTM misquantification. A CTM-RTH discordance (>1 log IU/ml) was found in 14/45 samples that had low pVLs and were successfully genotyped (pVL genoS). PreC/C clones of concordant (C1, C2) and discordant (D1, D2) strains were used to challenge the CTM. Strains D1 and D2 were highly underquantified (42- and 368-fold). In clones, mutating the region corresponding to the CTM reverse primer from a discordant sequence to a concordant sequence restored the levels of quantification to 24% (D1→C1) and 59% (D2→C1) of theoretical levels, while mutating the sequence of a concordant strain to that of a discordant strain led to 78-fold (C1→D1) and 146-fold (C1→D2) decreases in quantification. Moreover, mutating positions 1961 and 1962 was enough to induce a 5-fold underquantification. We conclude that the CTM underestimates pVLs for HBV strains with mutations in the reverse primer target. Specifically, the polymorphism at nucleotides 1961 and 1962 is naturally present in 4.79 and 4.22% of genotype A and D strains, which are highly frequent in Europe, leading to a 5-fold decrease in quantification. Quantification using the new-generation Roche C4800 assay is not affected by this polymorphism.
乙型肝炎病毒(HBV)的高基因变异性会影响DNA定量。在此,我们研究了cobas TaqMan HBV检测法(CTM;罗氏公司)对HBV的严重定量不足问题。在法国,2005年至2017年间,使用CTM在3102份献血中检测到HBV DNA(95%检测限[LOD],4.8 IU/ml)。对HBV毒株的S区域进行测序(LOD,约30 IU/ml)。根据CTM测定的血浆病毒载量(pVL)与测序结果之间的一致性,确定了一致(=120)和不一致(=45)的样本;所有样本也使用实时HBV检测法(RTH;雅培公司)进行了定量。采用病毒特征分析、克隆和诱变来表征导致CTM定量错误的多态性。在14/45份pVL较低且成功进行基因分型(pVL genoS)的样本中发现了CTM-RTH不一致(>1 log IU/ml)。使用一致(C1、C2)和不一致(D1、D2)毒株的前C/C克隆来检测CTM。D1和D2毒株被严重低估(分别低42倍和368倍)。在克隆中,将与CTM反向引物对应的区域从不一致序列突变为一致序列后,定量水平恢复到理论水平的24%(D1→C1)和59%(D2→C1),而将一致毒株的序列突变为不一致毒株的序列导致定量水平分别降低78倍(C1→D1)和146倍(C1→D2)。此外,突变1961和1962位点足以导致5倍的定量不足。我们得出结论:对于反向引物靶标发生突变的HBV毒株,CTM会低估pVL。具体而言,在欧洲非常常见的A和D基因型毒株中,1961和1962位点的核苷酸多态性自然存在的比例分别为4.79%和4.22%,导致定量降低5倍。使用新一代罗氏C4800检测法进行定量不受这种多态性的影响。